The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Obesity, insulin resistance, and type 1 diabetes mellitus
Abstract
PURPOSE OF REVIEW: To summarize recent studies about obesity, insulin resistance, and type 1 diabetes mellitus (T1DM). RECENT FINDINGS: Overweight and obesity continue to be prevalent among individuals with T1DM. Obesity rates appear to have reached a plateau among children with T1DM in some parts of the world. The risk for development of T1DM is increased by obesity and may occur at an earlier age among obese individuals with a predisposition. Obesity increases the risk for comorbidities among individuals with T1DM, especially metabolic syndrome, and microvascular and macrovascular diseases. Metformin, glucagon-like peptide-1 agonist therapy, sodium glucose cotransporter-2 inhibitor therapy, and bariatric surgery may be beneficial therapies for glucose control, comorbidity management, and obesity among adults with T1DM. Insulin resistance may be improved among obese individuals with T1DM by biguanides (metformin) and glucagon-like peptide-1 agonists (exenatide). SUMMARY: We review the last 18 months of literature on obesity, insulin resistance, and T1DM to highlight new epidemiologic results and treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there are multiple factors, particular obesity, increase the levels of adipocytes, inflammatory cytokines (IL-1, IL-6, and TNFα) (91).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [91]
Citations
Cites
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
Wilkin, T. J. (2001) · Diabetologia · doi:10.1007/s001250100548 · Cited by 623
Liu, L. L., Lawrence, J. M., Davis, C., Liese, A. D., Pettitt, D. J., Pihoker, C., Dabelea, D., Hamman, R. F., Waitzfelder, B., Kahn, H. S., et al. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00519.x · Cited by 404
Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort
Harpsøe, M. C., Basit, S., Andersson, M., Nielsen, N. M., Frisch, M., Wohlfahrt, J., Nohr, E. A., Linneberg, A. R., & Jess, T. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu045 · Cited by 248
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Menezes, H. T., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 232
The use of metformin in type 1 diabetes: a systematic review of efficacy
Vella, S., Buetow, L., Royle, P., Livingstone, S., Colhoun, H. M., & Petrie, J. R. (2010) · Diabetologia · doi:10.1007/s00125-009-1636-9 · Cited by 201
Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis
Dahlquist, G. G. (2005) · Diabetologia · doi:10.1007/s00125-005-0076-4 · Cited by 197
Type 1 diabetes, metabolic syndrome and cardiovascular risk
Chillarón, J. J., Flores Le-Roux, J. A., Benaiges, D., & Pedro-Botet, J. (2014) · Metabolism · doi:10.1016/j.metabol.2013.10.002 · Cited by 195
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
Fröhlich-Reiterer, E. E., Rosenbauer, J., Pozza, S. B., Hofer, S. E., Schober, E., Holl, R. W., & on behalf of the DPV-Wiss Study Group and the German BMBF Competence Networks Diabetes mellitus and Obesity (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304237 · Cited by 128
Cited by
Sorted by citations
Gut microbiota: a new path to treat obesity
Muscogiuri, G., Cantone, E., Cassarano, S., Tuccinardi, D., Barrea, L., Savastano, S., & Colao, A. (2019) · International Journal of Obesity Supplements · doi:10.1038/s41367-019-0011-7 · Cited by 370
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 361
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Obesity and Associated Comorbidities in People and Companion Animals: A One Health Perspective
Chandler, M. L., Cunningham, S. A., Lund, E., Khanna, C., Naramore, R., Patel, A. V., & Day, M. J. (2017) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2017.03.006 · Cited by 240
Phytosterols: Nutritional Health Players in the Management of Obesity and Its Related Disorders
Vezza, T., Canet, F., Marañón, A., Bañuls, C., Rocha, M., & Víctor, V. M. (2020) · Antioxidants · doi:10.3390/antiox9121266 · Cited by 136
Metadata
- Authors
- Polsky, S., & Ellis, S. L.
- Affiliations
- University of Colorado Anschutz (US)
- Corresponding author
- Polsky, Sarit
- ORCID
- Polsky, Sarit
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2015-08
- Volume
- 22
- Issue
- 4
- Pages
- 277-282
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2184822581
- Cited by
- 235
- References
- 27
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 29 · 2023: 21 · 2022: 35 · 2021: 27 · 2020: 26 · 2019: 23 · 2018: 21 · 2017: 18 · 2016: 10 · 2015: 4
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, obesity, insulin resistance, childhood obesity, metabolic syndrome, microvascular complications, macrovascular complications, metformin, biguanides, GLP-1 receptor agonists, exenatide, SGLT2 inhibitors, bariatric surgery
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Insulin Resistance, Obesity, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
